| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 55,984 | 13,237 | ||
| Short-term investments | 346,629 | 244,152 | ||
| Receivable from former related party | 0 | 0 | ||
| Accounts receivable, net | 5,000 | 39 | ||
| Prepaid expenses and other current assets | 6,212 | 6,177 | ||
| Total current assets | 413,825 | 263,605 | ||
| Long-term investments | 152,874 | 51,705 | ||
| Property and equipment, gross | 462 | - | ||
| Less accumulated depreciation | 277 | - | ||
| Property and equipment, net | 185 | 207 | ||
| Right-of-use operating lease assets | 1,306 | 1,378 | ||
| Other assets and restricted cash | 9,255 | 9,181 | ||
| Total assets | 577,445 | 326,076 | ||
| Accounts payable | 6,705 | 5,404 | ||
| Accrued expenses | 15,979 | 13,999 | ||
| Current portion of deferred revenue | 954 | 479 | ||
| Current portion of operating lease liabilities | 217 | 211 | ||
| Total current liabilities | 23,855 | 20,093 | ||
| Deferred revenue | 6,068 | 1,785 | ||
| Long-term operating lease liabilities | 1,068 | 1,119 | ||
| Total liabilities | 30,991 | 22,997 | ||
| Common stock 0.001 par value per share authorized shares - 150,000,000 at september 30, 2025 and december 31, 2024 issued and outstanding shares - 42,854,563 and 31,115,341 at september 30, 2025 and december 31, 2024, respectively | 43 | 32 | ||
| Additional paid-in capital | 818,545 | 538,481 | ||
| Accumulated deficit | -272,297 | -235,532 | ||
| Accumulated other comprehensive income | 163 | 98 | ||
| Total stockholders' equity | 546,454 | 303,079 | ||
| Total liabilities and stockholders' equity | 577,445 | 326,076 | ||
Dianthus Therapeutics, Inc. DE (DNTH)
Dianthus Therapeutics, Inc. DE (DNTH)